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Abstract: Zosyn®, also known as Tazocin® for injection, contains piperacillin and tazobactam and 
was approved by the US Food and Drug Administration in 1993 for the treatment of indicated serious 
infections. In 1995, United States Pharmacopoeia and European Pharmacopoeias reduced the particulate 
limit for injectables by 40%, based on general safety concerns. Wyeth attempted to control sporadic 
batch failures (associated with increased particulate formation) by shortening product expiration dating 
from 36 to 24 months and optimizing the stopper siliconization process. These modiﬁ  cations did not 
correct the problem completely. Wyeth reformulated Zosyn by incorporating two stabilizing functional 
excipients, ethylene diamine tetraacetic acid disodium salt (EDTA disodium) and sodium citrate, which 
solved the particulate formation problem. These two functional excipients also allowed for the ﬁ  rst 
time Y-site coadministration of reformulated Zosyn product with amikacin and gentamicin at speciﬁ  c 
doses and concentrations, and with certain diluents, and the use of Ca++ ion-containing Lactated 
Ringer’s for admixture preparation. Reformulated Zosyn (approved 2005) may provide useful options 
of drug administration to healthcare professionals to lessen levels of particulates. Supportive data is 
provided for the expanded compatibility of reformulated Zosyn with different types of Ringer’s solut-
ions used globally and for the Y-site coadministration of amikacin and gentamicin aminoglycosides.
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Introduction
Zosyn® background information
Zosyn®, also known as Tazocin® piperacillin/tazobactam (Wyeth Pharmaceuticals Inc., 
Philadelphia, PA, USA), is an intravenously administered antibiotic which is composed 
at an 8:1 ratio of piperacillin (a semisynthetic β-lactam) and tazobactam (a β-lactamase 
inhibitor derived from the penicillin nucleus). The Food and Drug Administration (FDA) 
approved it for use in the United States in 1993. Zosyn is currently used in hospitals 
worldwide to treat patients with moderate-to-severe infections caused by piperacillin-
resistant, piperacillin/tazobactam-susceptible β-lactamase-producing strains of certain 
speciﬁ  ed microorganisms. Zosyn is indicated for the treatment of moderate to severe 
hospital-acquired pneumonia, complicated intra-abdominal infections, complicated skin 
and soft tissue infections (Wyeth Prescribing Information [Glass vials] 2007; Wyeth 
Prescribing Information [Galaxy® bags] 2007), and moderate community-acquired 
pneumonia. Zosyn and Tazocin represent the same product sold by Wyeth in different 
countries and are used interchangeably in this communication.
History of reformulation of Zosyn
Zosyn, as an injectable antibiotic, is reconstituted and admixed with a variety of dilu-
ents before it is administered to a patient. Post-approval, during the 1990’s, Zosyn Therapeutics and Clinical Risk Management 2008:4(2) 304
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had sporadic batch failures related to subvisible particulate 
matter when conducting the usual Particulate Matter Test 
(United States Pharmacopoeia [USP] 788), at the new 
drug application (NDA) limits of 10,000 (particles 10 µM 
per small volume dose)/1,000 (particles 25 µM per small 
volume dose).
Two key factors identiﬁ  ed as responsible for excessive 
particulates were: (1) small traces of nontoxic silicone oil 
used to lubricate the elastomeric closures were dispersed 
in the reconstituted product as an emulsion. The dispersed 
silicone oil emulsion particles were interpreted by the HIAC 
particle size analyzer as solid particulate matter, contributing 
to the out of speciﬁ  cation results for sub-visible particulate 
matter and, (2) subvisible particulate counts increased with 
the age of the ﬁ  nished product associated with down-shift 
in the pH of the reconstituted solution of the drug product 
towards the acidic side.
In response, Wyeth modiﬁ  ed its container closure to 
control silicone lubricant from the rubber stopper insertion 
process. In addition, the product expiry dating was shortened 
from 36 to 24 months, as a slight increase occurred in the 
particulate matter test results in aged product. However, even 
with these changes, the product still experienced sporadic 
failures related to particulates. In 1995, USP and European 
Pharmacopeias adjusted the limits for particulates down-
wards in part due to ongoing awareness that particulates have 
the potential to cause morbidity or mortality in patients and 
because particulate matter had been linked to injection site 
reactions and thromboembolic events (Longe 1980; Falchuk 
et al 1985; Lehr et al 2002).
In 2001, partially in response to FDA requests regarding 
another Wyeth intravenous (IV) product and partially because 
of FDA concerns about Zosyn, Wyeth undertook to ensure 
that Zosyn met the revised (1995) USP 788 speciﬁ  cations. 
The revised speciﬁ  cations lowered the acceptable levels of 
subvisible particulate matter from 10,000 (particles 10 µM 
per small volume dose)/1,000 (particles 25 µM per small 
volume dose) to 6,000 (particles 10 µM per small volume 
dose)/600 (particles 25 µM per small volume dose). This 
corresponds to a required reduction in the acceptable number 
of 10 µm and 25 µm particle counts by 40%.
To accomplish this, Wyeth conducted due diligence 
investigations to establish the root cause and discovered 
that low pH and trace metal ions can be encountered (Desai 
et al 2007a, 2007b) through the use of various commercial 
diluents. Both factors may increase the rate of particulate 
matter formation in admixtures prepared from Zosyn and 
potentially penicillins and other β-lactams. This can cause 
the products to fail USP 788. The particulate failures in 
Zosyn may occur even though the pH of the drug substance 
is in its approved range of 5.5 to 6.8. Wyeth took corrective 
action by reformulating Zosyn.
Additional limitations of the original 
formulation and associated stability 
problems
In 1993, when Zosyn was introduced, its label instructed that 
the mixing of Zosyn with an aminoglycoside in vitro can result 
in substantial inactivation of the aminoglycoside. Chemical 
degradation of the aminoglycoside (possibly involving micro-
biologically inactive penicillin-aminoglycoside complexes 
or metal ion leachables) was observed to result in subpotent 
doses of the aminoglycoside. Such coadministration was 
also believed to lead to an unacceptably high particulate load 
(Desai et al 2007a, 2007b). In addition, the label of Zosyn 
instructed that lactated Ringer’s injection solution (LRS) was 
not compatible with Zosyn and hence could not be used as a 
reconstitution or admixture diluent.
Transition metal ions as leachables
from exogenous/endogenous sources
Contaminants in a drug product solution are deﬁ  ned as 
“leachables.” Potentially contaminating components of the 
drug product’s container system are termed “extractables.” 
Potential links between these two types of compounds 
have formed much of the basis for the increased scrutiny 
associated with revisions to the USP-NF and its General 
Chapter 788 standards for particulate matter in inject-
able solutions. Jenke (2005) recently proposed a paradigm 
for the assessment of interaction between these two classes 
of compounds based upon the origin of and ability to detect 
extractables in containers, relative to drug substances they 
may contain. This report cites the example of a regulatory 
body imposing a requirement of knowledge of such a linkage 
upon a drug manufacturer, and its potential impact upon a 
product’s life cycle (Jenke 2005).
Reformulation of Zosyn to overcome 
limitations
Desai and colleagues (2007a, 2007b) recently reported that 
there is signiﬁ  cant inter- and intra-batch variability in both 
pH and zinc ion content in commercially available IV diluents 
and solutions across different US manufacturers. Health-
care practitioners administering drugs in these diluents are 
generally not aware of this variability. In addition, since zinc Therapeutics and Clinical Risk Management 2008:4(2) 305
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is a common transition metal in drug-container packaging 
and delivery systems, it can leach into the IV solution from 
container components as well, and inactivate a drug via 
catalysis (Desai et al 2007a, 2007b).
Commonly used IV diluents may contain small amounts 
of a variety of exogenous inorganic ions and/or organic sub-
stances extracted from the containers and closures into the 
product during manufacturing or storage. Zinc oxide is used 
as ﬁ  ller in rubber elastomeric closures of vials, septa at the 
necks of infusion bags, or in the plungers of infusion syringes. 
Zinc-based organic substances are also used as polymerization 
initiators for the polymers used for the construction of admix-
ture bags or infusion line tubing. Zinc and other transition 
metal ions are known to catalyze chemical degradation of drug 
molecules (Bandoh et al 1991; Desai et al 2007a, 2007b).
Degradation pathways of antibiotics may include acid 
hydrolysis, ß-lactam ring opening (Bandoh et al 1991), or 
epimerization. In the case of ionizable drugs generating 
anionic species, zinc, calcium, and other metal ions are 
known to form insoluble solid particulates. In the clinical 
ﬁ  eld, risks associated with the injection of intravenous/
intrathecal solutions with particulate contamination are well 
documented (Nath et al 2004).
The target pH listed on the diluent bags from commercial 
suppliers can be 3.2 to 6.5 for 5% dextrose injection, and 
4.5 to 7.0 for 0.9% sodium chloride injection. The low pH 
extremes of 3.2 (for 5% dextrose injection) and 4.5 (for 0.9% 
sodium chloride injection) are considered to be acidic, thus 
having the potential to accelerate drug degradation, especially 
in the presence of zinc (Desai et al 2007a, 2007b).
Thus, for the therapeutic performance and safety of drug 
admixtures infused by the IV route, having data of the pH and 
levels of zinc in commercial diluents from various parenteral 
manufacturers is crucial. Since this information is not readily 
available to the health professionals preparing the solution for 
parenteral administration, the availability of a drug product 
resilient to pH or trace metal ion levels commonly found in 
the clinical setting is preferable.
As part of the root cause analysis, the particulates were 
isolated and conﬁ  rmed to be dimers of piperacillin by spec-
troscopic characterization. The chemical pathway for the 
dimer formation is shown in Figure 1.
After extensive research, particulate formation in Zosyn 
was found to be related to the opening of the β-lactam ring 
of piperacillin, which is accelerated in acidic pH solutions, 
and is followed by the dimerization of piperacillin molecules 
that may be further catalyzed by zinc ions.
In summary, the presence of zinc may contribute to 
incompatibility by: (1) catalysis of drug degradation and 
potential underdosing, and (2) generation of insoluble solid 
particulate matter from the dimer formation and/or chelation 
with ionic species of the drug. Thus, Desai and colleagues 
(2007a, 2007b)concluded that it is highly desirable that 
all new drug molecules be screened in the early product 
Figure 1 Hydrolysis of piperacillin followed by formation of a piperacillin dimer with low solubility.Therapeutics and Clinical Risk Management 2008:4(2) 306
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development phase for susceptibility to catalysis by zinc, 
and that the drug product be designed from the outset with 
sufﬁ  cient robustness to withstand exposure to variable 
amounts of zinc ion. It is also recommended that USP 
monographs address the potential issues posed by zinc in the 
drug manufacturing and dosage form infusion process.
Combination therapy with Zosyn
and amikacin/gentamicin
Because of the prevalent clinical need to administer piper-
acillin/tazobactam in combination with the aminoglycosides 
amikacin or gentamicin to treat nosocomial pneumonia 
caused by Pseudomonas aeruginosa as well as conditions 
caused by other pathogens, the clinician often faces opera-
tional challenges: either administer Zosyn and amikacin 
or gentamicin separately, or through the same intravenous 
line, typically through a Y-site tube. The latter mode, if pos-
sible, would expedite the treatment of the patients in critical 
care. Mixing of the original formulation of Zosyn with an 
aminoglycoside in vitro resulted in substantial inactivation 
of the aminoglycoside by piperacillin. It was postulated 
that penicillin-aminoglycoside complexes are created that 
are microbiologically inactive and are of unknown toxicity 
(Benveniste and Davis 1973; Glew and Pavuk 1983).
Evaluation of reformulated Zosyn
to expand compatibility
The compatibility of reformulated Zosyn was evaluated by 
different physicochemical and spectroscopic methods to show 
that it can be coadministered as admixture with different types 
of Ringer’s solutions which was not feasible with the original 
Zosyn. Also, the feasibility of Y-site coadministration with 
amikacin or gentamicin aminoglycosides was evaluated as 
shown in the following sections.
Materials and methods
The samples of reformulated Zosyn from Wyeth, used in the 
admixture diluent compatibility and Y-site aminoglycoside 
studies, were manufactured and released as per approved 
product speciﬁ  cations. Commercial intravenous diluents, 
amikacin and gentamicin antibiotic products were purchased 
from US/German or other European countries and were used 
within expiry dating.
For the simulated Y-site administration study, reformulated 
Zosyn was admixed in a (high dose, low dose) crossover with 
two different gentamicin drug products in a (high dose, low dose) 
matrix design. The crossover pairings of reformulated Zosyn 
and gentamicin were based on the dose extremes expected in 
clinical use and were derived from the label dosing instructions 
listed on the package insert for each drug product.
The subvisible particulate (10 and 25 µm) counts were 
measured by the HIAC light obscuration method described 
in USP788 and equivalent EU pharmacopeia 5.0 (2004) 
2.9.19 sections.
Typical HPLC assay methods were used for potency 
determinations of amikacin, piperacillin, and tazobactam in 
the presence of reformulated Zosyn components.
For gentamicin potency determinations in the presence of 
reformulated Zosyn components, it was necessary to design a 
customized nuclear magnetic resonance (NMR) method. For 
the NMR study, it was necessary to remove the water from the 
commercial gentamicin product by lyophilization. The simulated 
Y-site samples were prepared by dissolving lyophilized genta-
micin and reformulated Zosyn (lyophilized powder) in D2O in 
accordance with the concentration matrix described in Table 1.
Initially, the NMR method by Professor Holzgrabe 
(Winters 2005) was evaluated to quantify gentamicin 
potency in the presence of reformulated Zosyn as a function 
of time. The NMR method appears to be applicable only to 
Table 1 Combination matrix for reformulated Tazocin® plus gentamicin
Combination matrix for reformulated Tazocin® plus gentamicin (reconstituted and diluted in D2O) at clinically relevant bracketed 
ranges of concentrations
Tazocin sample    Concentration [Pip] and [Tazo]  Gentamicin
  mg/mL in the “bag”a  mg/mL in the Y-site sampleb  mg/mL in the “bag”a  mg/mL in the Y-site sampleb
Reformulated Tazocin High case  40.0 and 5.0  20.0 and 2.5  3.32 High case  1.66
Reformulated Tazocin High case  40.0 and 5.0  20.0 and 2.5  0.7 Low case  0.35
Reformulated Tazocin Low case  13.33 and 1.67  6.67 and 0.84  3.32 High case  1.66
Reformulated Tazocin Low case  13.33 and 1.67  6.67 and 0.84  0.7 Low case  0.35
Notes: aThe concentrations listed represent the calculated theoretical high and low concentrations that a hospital pharmacist would prepare in separate intravenous infusion 
bags for reformulated Tazocin and gentamicin; bWhen infused through a Y-site tube, each drug solution will be infused at the same rate. Thus, the resulting admixture solution 
infused intravenously to the patient will have a ﬁ  nal concentration that is half of the concentrations listed above in each individual bag. Therefore, to simulate this practice, the 
ﬁ  nal admixtures will be prepared at concentrations that are half what is listed in the table (eg, For “High Tazocin” – “High Gentamicin” Y-site infusion simulation the sample 
will be prepared at approximately 20 mg/ml of piperacillin, 2.5 mg/ml of tazobactam, and 1.66 mg/ml of gentamicin in D2O.).Therapeutics and Clinical Risk Management 2008:4(2) 307
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gentamicin drug product as-is, with a low ambient pH of 
about 4 to 4.6. Upon the addition of reformulated Zosyn, the 
ﬁ  nal pH of the simulated Y-site solution with gentamicin is 
raised to about 6, so the ionic environment of the anomeric 
protons and the –N-methyl protons is changed, and hence the 
NMR spectrum is totally different than that of gentamicin 
drug product alone as observed by the Holzgrabe group.
For the customized NMR method, two groups of proton 
resonances of gentamicin were isolated from other proton 
resonances and were explored for the quantiﬁ  cation of genta-
micin. One is from the anomeric protons at δH 5.84 (doublet) 
and δH 5.80 (multiplet). The other is from the N-methyl group 
at δH 2.85 (singlet). Although the anomeric proton resonances 
were well separated, due to the relatively low concentration 
of gentamicin used in the clinical admixtures, the observed 
signal-to-noise ratio for the anomeric protons was very low. 
The N-methyl proton resonance peaks (with very good sepa-
ration from the other peaks, and a peak intensity signiﬁ  cantly 
higher than the anomeric proton peaks) were considered more 
appropriate to provide quantiﬁ  cation of clinically relevant 
parenteral admixtures with low levels of gentamicin in the 
presence of very high levels of reformulated Zosyn.
NMR experiments were performed at room temperature 
on a Bruker DRX-500 NMR spectrometer, operating at 
500.13 MHz (1H), equipped with TOPSPIN software 
(Version 1.3). 112 scans were collected into 64 k data points 
giving a digital resolution of 0.16 Hz per point. The spectral 
width was 10330 Hz, the transmitter offset at 6.17 ppm, and 
the ﬂ  ip angle was 90°. Using an acquisition time of 3.17 s 
and an additional delay of 1 s, the pulse repetition period was 
about 4.17 s. Samples were measured in D2O at 298 K. Each 
1H NMR data point for gentamicin represents cumulative 
scans collected over ten minutes.
Hydroquinone monoethyl ether was used as an internal 
standard due to the absence of chemical interactions with 
gentamicin and all components of reformulated Zosyn. 
Also, the associated peaks of the hydroquinone monoethyl 
ether protons do not overlap or cause interference with the 
N-methyl protons of gentamicin that were used for quanti-
ﬁ  cation. This customized NMR method provides a kinetic 
snapshot at 10-minute intervals over a period of 1 hour for 
gentamicin strength in the presence of reformulated Zosyn.
Results and discussion
Improved clinical utility of the 
reformulated version of Zosyn
In 2005 (USP 788 2007), the FDA approved the new 
formulation of Zosyn that complies with USP788 
particulate speciﬁ  cations and has an expanded compatibility 
proﬁ  le with the aminoglycosides, amikacin and gentamicin. 
The modiﬁ  cations to the formulation consisted of the addi-
tion of the disodium salt of ethylene diamine tetraacetic acid 
(disodium EDTA; edetate disodium dihydrate), which acts 
as a metal-chelating agent, and sodium citrate, which acts as 
a buffer. These modiﬁ  cations lessen the possibility of par-
ticulate matter accumulation during storage of the solution 
form of Zosyn or the development of particulate matter upon 
reconstitution of Zosyn lyophilized powder with commonly 
used diluents. In addition, reformulated Zosyn can be admin-
istered simultaneously, either with amikacin or gentamicin, 
via Y-site infusion at speciﬁ  c doses and concentrations, 
and with certain diluents (Wyeth Prescribing Information 
[Glass vials] 2007a; Wyeth Prescribing Information [Galaxy® 
bags] 2007b).
Also, unlike original Zosyn, reformulated Zosyn has been 
shown (Table 2) to be compatible with LRS or Hartmann’s 
solution (European version of LRS) for dilution. Healthcare prac-
titioners sometimes prefer to use LRS or Hartmann’s solution.
Allowance of Y-site coadministration of 
reformulated Zosyn with aminoglycosides
The inactivation of aminoglycosides in the presence of 
penicillin-class drugs containing β-lactam rings has been 
recognized (Benveniste and Davis 1973; Glew and Pavuk 
1983). However, amikacin and gentamicin have been shown 
to be compatible in vitro with reformulated Zosyn containing 
disodium EDTA supplied in vials or bulk pharmacy contain-
ers in certain diluents at speciﬁ  c doses and concentrations 
for a simultaneous Y-site infusion.
Simulated Y-site administration studies by Wyeth 
were conducted for reformulated Zosyn with amikacin or 
gentamicin in the concentration ranges and clinical doses 
described in the labels of Zosyn and each of the aminogly-
cosides. The simulated studies mimicked Y-site coadminis-
tration for Zosyn-amikacin systems and evaluated potency 
and degradation products by HPLC analyses (Tables 3 
and 4). Reformulated Zosyn was shown to be compatible 
for simultaneous administration via a Y-site intravenous 
tube with amikacin in the concentration ranges of 2.25 g 
reformulated Zosyn/150 mL to 4.5 g/50 mL for Zosyn and 
1.75 mg/mL to 7.5 mg/mL for amikacin in sterile water for 
injection, USP and 0.9% sodium chloride injection, USP, 5% 
dextrose in water for injection, USP and lactated Ringer’s 
injection, USP (Table 5). Degradation products and related 
compounds in the solution were quantiﬁ  ed in a further 
study, which conﬁ  rmed the ﬁ  rst study’s conclusions, and Therapeutics and Clinical Risk Management 2008:4(2) 308
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Table 2 Summary of drug potency results for admixtures of reformulated Zosyn® in various diluents and stored at room temperature 
for up to 24 hours
Diluent  Time   Theoretical values   Observed values 
 point  (mg/mL)    (mg/mL)
  (Hours)  [PIP]  [TAZO]  [PIP]  % Initial PIP  [TAZO]  % Initial TAZO  pH
Saline 0  80.0  10.0  79.91  100.0  10.05  100.0  6.21
Saline 24  80.0  10.0  79.14  99.0  9.90  98.5  6.04
WFI 0  80.0  10.0  77.28  100.0  9.72  100.0  6.48
WFI 24  80.0  10.0  79.26  102.6  9.94  102.2  6.24
D5W 0  80.0  10.0  79.17  100.0  9.95  100.0  6.43
D5W 24  80.0  10.0  77.96  98.5  9.75  98.0  6.23
Compound sodium lactate  0  16.0  2.0  15.32  100.0  1.93  100.0  6.10
intravenous infusion BP
(Hartmann’s solution)
Compound sodium lactate   24  16.0  2.0  14.68  95.8  1.84  95.3  5.92
intravenous infusion BP
(Hartmann’s solution)
Saline 0  13.33  1.67  13.79  100.0  1.71  100.0  6.30
Saline 24  13.33  1.67  13.92  100.9  1.72  100.6  6.03
WFI 0  40.0  5.0  38.16  100.0  4.75  100.0  6.53
WFI 24  40.0  5.0  38.83  101.8  4.80  101.1  6.33
D5W 0  13.33  1.67  13.16  100.0  1.63  100.0  6.59
D5W 24  13.33  1.67  13.69  104.0  1.69  103.7  6.31
Compound sodium lactate  0  8.0  1.0  8.32  100.0  1.03  100.0  6.09
intravenous infusion BP
(Hartmann’s solution)
Compound sodium lactate  24  8.0  1.0  8.25  99.2  1.02  99.0  5.90
intravenous infusion BP
(Hartmann’s solution)
Abbreviations: PIP, Piperacillin; Saline, 0.9% NaCl solution; TAZO, Tazobactam; WFI, water for injection; D5W, 5% dextrose solution.
Table 3 Summary of drug potency results for simulated Y-site coadministration of reformulated Zosyn® with amikacin in compound 
sodium lactate intravenous infusion BP (Hartmann’s solution) at room temperature
Time point  Theoretical values (mg/mL)  Observed potency (mg/mL) and % Remaining of three Antibiotics
(Hours)  [Pip]  [Tazo]  [Amik]  [Pip]  % Initial Pip  [Tazo]  % Initial Tazo  [Amik]  % Initial Amik  pH
0  8.0  1.0 3.75 8.03  100.0  1.00  100.0  3.75 100.0  5.39
1  8.0  1.0 3.75 8.02  99.9  1.00  100.0  3.75 100.0  5.36
2  8.0  1.0 3.75 8.04  100.1  1.00  100.0  3.74 100.0  5.36
4  8.0  1.0 3.75 8.02  99.9  1.00  100.0  3.77 100.5  5.35
0  8.0  1.0 0.875  8.18  100.0  1.02  100.0  0.88 100.0  5.65
1  8.0  1.0 0.875  8.06  98.5  1.00  98.0  0.88 100.0  5.64
2  8.0  1.0 0.875  8.13  99.4  1.01  99.0  0.89 101.1  5.66
4  8.0  1.0 0.875  8.18  100.0  1.02  100.0  0.89 101.1  5.65
0  4.0  0.5 3.75 4.19  100.0  0.52  100.0  3.76 100.0  5.31
1  4.0  0.5 3.75 4.19  100.0  0.52  100.0  3.76 100.0  5.30
2  4.0  0.5 3.75 4.22  100.7  0.52  100.0  3.77 100.2  5.30
4  4.0  0.5 3.75 4.15  99.0  0.51  98.1  3.75 99.7  5.29
0  4.0  0.5 0.875  4.35  100.0  0.53  100.0  0.88 100.0  5.60
1  4.0  0.5 0.875  4.35  100.0  0.54  101.9  0.88 100.0  5.59
2  4.0  0.5 0.875  4.36  100.2  0.54  101.9  0.89 101.1  5.60
4  4.0  0.5 0.875  4.28  98.4  0.53  100.0  0.89 101.1  5.59
Note: The same intravenous diluent was used to reconstitute the lyophilized drug and to prepare the intravenous infusion at the proper concentration for administration 
to the patient. In this case it was compound sodium lactate intravenous infusion BP (Hartmann’s solution).
Abbreviations: Amik, amikacin; Pip, piperacillin; Tazo, Tazobactam.Therapeutics and Clinical Risk Management 2008:4(2) 309
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Table 4 Degradation products of reformulated Zosyn® drug components in the presence of amikacin up to 4 hours at room temperature 
in compound sodium lactate intravenous infusion BP (Hartmann’s solution)
Time point  Theoretical potency   % of degradation productsa of Zosyn® drug components
(Hours) (mg/mL)    RRT 0.104  RRT 0.516  RRT 0.564  RRT 0.591  RRT 0.635
  [Pip]/[Tazo]  [Amik]      
0 8.0/1.0  3.75  0.056  0.59  –  0.078  –
1 8.0/1.0  3.75  0.067  0.72  –  0.078  –
2 8.0/1.0  3.75  0.067  0.89  –  0.078  –
4 8.0/1.0  3.75  0.078  1.13  –  0.067  –
0 8.0/1.0  0.875  0.067  0.56  –  0.078  –
1 8.0/1.0  0.875  0.067  0.58  –  0.078  –
2 8.0/1.0  0.875  0.067  0.62  –  0.078  –
4 8.0/1.0  0.875  0.067  0.70  –  0.078  –
0  4.0/0.5  3.75  0.067  0.56 0.10 0.089  0.20
1 4.0/0.5  3.75  0.067  0.76  –  0.089  0.17
2 4.0/0.5  3.75  0.067  0.89  –  0.089  0.24
4 4.0/0.5  3.75  0.089  1.18  –  0.067  0.10
0 4.0/0.5  0.875  0.067  0.56  –  0.089  0.10
1 4.0/0.5  0.875  0.067  0.60  –  0.089  0.10
2 4.0/0.5  0.875  0.067  0.62  –  0.089  0.11
4 4.0/0.5  0.875  0.067  0.69  –  0.089  0.08
Abbreviations: RRT, Relative retention times of the HPLC chromatograms corresponding to the known degradation products of Zosyn® and amikacin in simulated y-site 
mixtures.
Notes: aThe observed % value of the degradation products are far below the approved speciﬁ  cations for the products.
showed that reformulated Zosyn (piperacillin/tazobactam) 
is compatible for Y-site coadministration with amikacin or 
gentamicin. US-sourced amikacin and gentamicin, evalu-
ated here, represent the composition ranges of the products 
prescribed globally.
The study designs used for Y-site compatibility and 
admixture stability are based on simulated Y-site injection 
testing procedures reported by Choi and colleagues (1994) 
and by Trissel and Martinez (1994a).
A follow-up simulated Y-site compatibility study, 
conducted by using an innovative NMR method, is 
supplementary to the previous study using an LC-MS method. 
The current study differs from the previous study in that it 
tested the simulated Y-site mixtures of reformulated Tazocin 
Table 5 Simulated Y-site coadministration of reformulated Zosyn® with amikacin in different admixture diluents (Potency of antibiotics 
at 4 hours)
Admixture diluent  Initial composition    % Antibiotic remaining of the initial
 Zosyn® (PIP mg/mL/  Amikacin  % Amikacin  % Tazobactam  % Piperacillin
 Tazo  mg/mL)  (mg/mL)
0.9% NaCl  80/10  7.5  95.7  98.6  98.7
0.9% NaCl  80/10  1.75  105.7  99.0  99.3
0.9% NaCl  13/1.7  7.5  99.8  98.5  98.8
0.9% NaCl  13/1.7  1.75  111.0  99.5  99.4
5% Dextrose  80/10  7.5  94.0  104.9  105.3
5% Dextrose  80/10  1.75  90.0  99.7  99.9
5% Dextrose  13/1.7  7.5  97.6  99.4  99.4
5% Dextrose  13/1.7  1.75  94.4  98.9  99.1
WFI/ 0.9% NaCl  80/10  7.5  99.2  98.6  98.9
WFI/ 0.9% NaCl  80/10  1.75  97.5  101.1  99.3
WFI/ 0.9% NaCl  13/1.7  7.5  100.3  96.2  97.8
WFI/ 0.9% NaCl  13/1.7  1.75  100.3  98.3  98.5
Lactated Ringers  16/2  7.5  93.3  99.0  98.3
Lactated Ringers  16/2  1.75  92.6  99.8  99.4
Lactated Ringers  8/1  7.5  99.7  98.6  99.0
Lactated Ringers  8/1  1.75  97.3  99.6  99.6
Abbreviations: WFI, water for injection; PIP, piperacillin; Tazo, Tazobactam.Therapeutics and Clinical Risk Management 2008:4(2) 310
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and gentamicin at shorter time intervals of 0, 10, 20, 30, 40, 50, 
and 60 minutes, while the previous study tested these mixtures 
at 0, 1, 2, and 4 hours. This change is to collect data at clini-
cally realistic shorter time intervals, because the 4-hour test-
ing time point represents an exaggerated contact time for the 
Y-site drug compatibility testing. In actual clinical practice, 
when two drugs are infused through a Y-site the maximum 
estimated contact time (prior to entering the blood stream) 
is short, often in the range of 15 minutes and not extending 
more than 60 minutes (Trissel 1994b; Leissing 1989). In this 
experiment to simulate Y-site administration, reformulated 
Tazocin was admixed in a (high dose, low dose) crossover 
with two gentamicin drug products sourced from Germany 
in a (high dose, low dose) matrix design, as shown in Table 
1. The crossover pairings of reformulated Tazocin and gen-
tamicin were based on the dose extremes expected in clinical 
use and were derived from the label dosing instructions listed 
on the package insert for each drug product.
Simulated Y-site stability results
The kinetic snapshot at every ten minutes over a period of 0 to 
60 minutes of the mixed solutions analyzed by evaluating the 
–N-methyl proton resonance of the gentamicin molecule in a 
noninvasive manner at room temperature shows the following:
(1) For both gentamicin products in all four combinations with 
reformulated Tazocin, the potency values of gentamicin at ten 
minutes are maintained at greater than 98% of the initial. As 
described earlier, the typical time for gentamicin and refor-
mulated Tazocin to remain in contact during the actual Y-site 
co-administration in a clinical setting is about 15 minutes.
(2) At 30 minutes and 60 minutes, better than 97% and 96% of 
the initial potency of gentamicin is maintained, respectively, 
even for the worst-case scenario of a solution mixture of 
“high” reformulated Tazocin and “low” gentamicin during a 
simulated Y-site administration. Based on the aminoglycoside 
and β-lactam interaction chemistry, the highest degradation 
of gentamicin was expected for this combination.
(3) As expected, for the “high” gentamicin combination with 
“low” or “high” reformulated Tazocin, the gentamicin 
strength at 60 minutes was found to be greater than 98%.
Representative data for Y-site compatibility at clinically 
relevant concentration ranges of reformulated Tazocin 
combined with another German gentamicin commercial 
drug product (Ratiopharm®) are provided in Table 6. Data 
Table 6 Reformulated Tazocin®: Simulated Y-site compatibility by NMR for Ratiopharm® German gentamicin drug product
Product Name Gentamicin - Ratiopharm® 40 SF
(40 mg/1 ml ampoule gentamicin, Ratiopharm® Company, Germany)
Components Gentamicin sulfate
Acetylcysteine
Na2EDTA
NAOH or H2SO4 for pH adjustment
WFI
Combination 
matrix in 
simulated y-site 
Prepared in D2O 
solution
High Tazo: High Genta
(20 mg/mL Pip: 1.6 mg/mL 
Genta)a
High Tazo: Low Genta
(20 mg/mL Pip: 0.35 mg/mL 
Genta)a
Low Tazo: High Genta
(6.67 mg/mL Pip: 1.6 mg/mL 
Genta)b
Low Tazo: Low Genta
(6.67 mg/mL Pip: 0.35 mg/mL 
Genta)b
Sample number L39609-28-1 L39609-28-2 L39609-28-3 L39609-28-4
Time (min) Relative peak 
area δH:2.85 
(-NCH3)c
% Initiald Relative peak 
area δH:2.85 
(-NCH3)c
% Initiald Relative peak 
area δH:2.85 
(-NCH3)c
% Initiald Relative peak 
area δH:2.85 
(-NCH3)c
% Initiald
0 1.7558 100 0.3942 100 1.8981 100 0.4194 100
10 1.7533 99.9 0.3881 98.5 1.8948 99.8 0.4170 99.4
20 1.7518 99.8 0.3846 97.6 1.8953 99.9 0.4183 99.7
30 1.7512 99.7 0.3847 97.6 1.8971 99.9 0.4131 98.5
40 1.7450 99.3 0.3792 96.2 1.8977 100.0 0.4135 98.6
50 1.7496 99.6 0.3784 96.0 1.8897 99.6 0.4116 98.1
60 1.7453 99.4 0.3806 96.5 1.8929 99.7 0.4102 97.8
Notes: aalso contains 2.5 mg/ml of tazobactam; balso contains 0.84 mg/ml of tazobactam; cobserved peak area for δH: 2.85 (-NCH3) of gentamicin is relative to internal 
standard of hydroquinone methyl ether; d% of initial concentration of gentamicin remaining.
Abbreviations: Tazo: Tazocin®; Pip, piperacillin.Therapeutics and Clinical Risk Management 2008:4(2) 311
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Table 7 Summary of subvisible particulate counts by HIAC for simulated Y-site coadministration of reformulated Zosyn® and amikacin
Sample 
description
Reconstitution 
solvent
Solution 
concentration
Aminoglycoside 
concentration
Admixture 
diluent
Particulate counts by HIAC
10 µm
t = 0 hrs
10 µm
t = 4 hrs
25 µm
t = 0 hrs
25 µm
t = 4 hrs
Particulate Count Speciﬁ  cations as per USP 788a NMT 6000 NMT 6000 NMT 600 NMT 600
Low Zosyn WFI 40 mg/mL 
piperacillin 
plus 5 mg/mL 
tazobactam
Amikacin
(7.5 mg/ml)
Saline 2595
2920
1875
1585
1320
3640
45
60
25
45
40
30
Low Zosyn WFI 40 mg/mL 
piperacillin 
plus 5 mg/mL 
tazobactam
Amikacin
(1.75 mg/ml)
Saline 4505
4265
4555
1265
1465
1450
70
35
80
0
20
25
High Zosyn WFI 80 mg/mL 
piperacillin 
plus 10 mg/mL 
tazobactam
Amikacin
(7.5 mg/ml)
Saline 4430
4270
2235
750
2290
3320
100
50
45
15
10
40
High Zosyn WFI 80 mg/mL 
piperacillin 
plus 10 mg/mL 
tazobactam
Amikacin
(1.75 mg/ml)
Saline 3780
4840
3965
1160
455
1255
50
105
25
35
0
35
Low Zosyn Saline 13.33 mg/mL 
piperacillin plus 
1.67 mg/mL 
tazobactam
Amikacin
(7.5 mg/ml)
Saline 845
1210
1600
1730
815
1250
15
15
20
35
65
45
Low Zosyn Saline 13.33 mg/mL 
piperacillin plus 
1.67 mg/mL 
tazobactam
Amikacin
(1.75 mg/ml)
Saline 555
1670
1940
2150
1890
1485
0
15
10
120
75
115
High Zosyn Saline 80 mg/mL 
piperacillin 
plus 10 mg/mL 
tazobactam
Amikacin
(7.5 mg/ml)
Saline 1015
3145
2320
5690
1295
5360
15
0
50
125
30
160
High Zosyn Saline 80 mg/mL 
piperacillin 
plus 10 mg/mL 
tazobactam
Amikacin
(1.75 mg/ml)
Saline 3960
1765
2150
1665
3225
1635
25
20
15
40
75
100
Low Zosyn Lactated Ringer’s 8 mg/mL piper-
acillin plus 1 mg/
mL tazobactam
Amikacin
(7.5 mg/ml)
Lactated 
Ringer’s
1180
915
640
185
285
580
5
0
5
0
0
0
Low Zosyn Lactated Ringer’s 8 mg/mL piper-
acillin plus 1 mg/
mL tazobactam
Amikacin
(1.75 mg/ml)
Lactated 
Ringer’s
505
490
815
285
365
170
15
5
0
0
5
10
High Zosyn Lactated Ringer’s 16 mg/mL 
piperacillin 
plus 2 mg/mL 
tazobactam
Amikacin
(7.5 mg/ml)
Lactated 
Ringer’s
645
635
1245
415
380
275
0
15
20
20
0
0
High Zosyn Lactated Ringer’s 16 mg/mL 
piperacillin 
plus 2 mg/mL 
tazobactam
Amikacin
(1.75 mg/ml)
Lactated 
Ringer’s
600
495
385
275
505
415
15
10
5
5
10
10
Abbreviations: NMT, not more than; WFI, water for injection; Saline, 0.9% sodium chloride.
Notes: aParticulate count speciﬁ  cations in EU and other Pharmacopeia are similar.Therapeutics and Clinical Risk Management 2008:4(2) 312
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Table 8 Summary of subvisible particulate counts by HIAC for simulated Y-site coadministration of reformulated Zosyn® and gentamicin
Sample 
description
Reconstitution 
solvent
Solution 
concentration
Aminoglycoside 
concentration
Admixture 
diluent
Particulate counts by HIAC
10 µm
t = 0 hrs
10 µm
t = 4 hrs
25 µm
t = 0 hrs
25 µm
t = 4 hrs
Particulate Count Speciﬁ  cations as per USP 788 NMT 6000 NMT 6000 NMT 600 NMT 600
Low Zosyn WFI 40 mg/mL 
piperacillin 
plus 5 mg/mL 
tazobactam
Gentamicin
(3.32 mg/ml)
Saline 545
435
570
1750
715
1555
20
5
15
5
10
15
Low Zosyn WFI 40 mg/mL 
piperacillin 
plus 5 mg/mL 
tazobactam
Gentamicin
(0.7 mg/ml)
Saline 550
1745
730
1435
390
395
5
5
10
50
5
15
High Zosyn WFI 80 mg/mL 
piperacillin 
plus 10 mg/mL 
tazobactam
Gentamicin
(3.32 mg/ml)
Saline 1470
1980
540
110
170
1110
35
10
0
0
25
60
High Zosyn WFI 80 mg/mL 
piperacillin 
plus 10 mg/mL 
tazobactam
Gentamicin
(0.7 mg/ml)
Saline 1170
2770
1465
600
310
210
30
20
20
50
5
20
Low Zosyn Saline 13.33 mg/mL 
piperacillin plus 
1.67 mg/mL 
tazobactam
Gentamicin
(3.32 mg/ml)
Saline 765
4220
2700
1465
1130
1485
5
145
35
70
30
50
Low Zosyn Saline 13.33 mg/mL 
piperacillin plus 
1.67 mg/mL 
tazobactam
Gentamicin
(0.7 mg/ml)
Saline 935
1500
1375
4425
2465
760
25
50
25
70
30
50
High Zosyn Saline 80 mg/mL 
piperacillin 
plus 10 mg/mL 
tazobactam
Gentamicin
(3.32 mg/ml)
Saline 3385
2275
2265
4120
2560
2660
140
35
60
140
110
120
High Zosyn Saline 80 mg/mL 
piperacillin 
plus 10 mg/mL 
tazobactam
Gentamicin
(0.7 mg/ml)
Saline 2035
5235
2790
1175
1865
1800
45
215
80
45
105
60
Low Zosyn 5% Dextrose 13.33 mg/mL 
piperacillin plus 
1.67 mg/mL 
tazobactam
Gentamicin
(3.32 mg/ml)
5% Dextrose 860
1175
695
540
435
445
25
25
20
165
75
95
Low Zosyn 5% Dextrose 13.33 mg/mL 
piperacillin plus 
1.67 mg/mL 
tazobactam
Gentamicin
(0.7 mg/ml)
5% Dextrose 515
310
505
190
165
305
20
5
10
15
20
15
High Zosyn 5% Dextrose 80 mg/mL 
piperacillin 
plus 10 mg/mL 
tazobactam
Gentamicin
(3.32 mg/ml)
5% Dextrose 2545
1905
1030
675
845
985
65
55
40
20
20
20
High Zosyn 5% Dextrose 80 mg/mL 
piperacillin 
plus 10 mg/mL 
tazobactam
Gentamicin
(0.7 mg/ml)
5% Dextrose 1860
2825
2240
690
680
630
25
15
10
20
5
25
Low Zosyn Lactated Ringer’s 8 mg/mL 
piperacillin 
plus 1 mg/mL 
tazobactam
Gentamicin
(3.32 mg/ml)
Lactated 
Ringer’s
1120
930
135
170
85
165
0
15
5
5
0
0
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Table 8 (Continued)
Sample 
description
Reconstitution 
solvent
Solution 
concentration
Aminoglycoside 
concentration
Admixture 
diluent
Particulate counts by HIAC
10 µm
t = 0 hrs
10 µm
t = 4 hrs
25 µm
t = 0 hrs
25 µm
t = 4 hrs
Particulate Count Speciﬁ  cations as per USP 788 NMT 6000 NMT 6000 NMT 600 NMT 600
Low Zosyn Lactated Ringer’s 8 mg/mL 
piperacillin 
plus 1 mg/mL 
tazobactam
Gentamicin
(0.7 mg/ml)
Lactated 
Ringer’s
1215
250
465
180
325
190
10
5
15
5
10
0
High Zosyn Lactated Ringer’s 16 mg/mL 
piperacillin 
plus 2 mg/mL 
tazobactam
Gentamicin
(3.32 mg/ml)
Lactated 
Ringer’s
325
870
1235
270
155
250
5
10
0
0
5
0
High Zosyn Lactated Ringer’s 16 mg/mL 
piperacillin 
plus 2 mg/mL 
tazobactam
Gentamicin
(0.7 mg/ml)
Lactated 
Ringer’s
375
410
630
330
205
270
15
5
5
0
0
5
Abbreviation: NMT, not more than.
for the Rebofacin gentamicin product (not shown here) were 
found to be similar.
Particulate matter evaluation
for reformulated Zosyn – amikacin
or gentamicin (simulated Y-site study)
The subvisible particle counts for 10 µm and 25 µm size were 
determined using the HIAC method. The particulate counts at 
0 and 4 hours for simulated Y-site mixtures of reformulated 
Zosyn and gentamicin or amikacin in admixtures of com-
mon commercial diluents are provided in Tables 7 and 8. 
The concentrations of reformulated Zosyn and gentamicin 
or amikacin were chosen to simulate clinically relevant dilu-
tions in the admixture infused. The particulate counts up to 
the 4 hour test period for the reformulated Zosyn – amikacin 
system and reformulated Zosyn – gentamicin system were well 
within the current USP and EU Pharmacopeia speciﬁ  cations. 
Reformulated Zosyn was shown to be compatible for coadmin-
istration via a Y-site intravenous tube with gentamicin under 
the concentration ranges of 2.25 g reformulated Zosyn/150 mL 
to 4.5 g/100 mL for Zosyn and 0.7 mg/mL to 3.32 mg/mL for 
gentamicin in the 0.9% sodium chloride injection USP coad-
ministration of Zosyn with 0.9% sodium chloride.
Conclusions
In summary, the product quality enhancement provides 
expanded ﬂ  exibility for the administration of reformulated 
Zosyn under variable clinical use conditions:
(1) Reformulated Zosyn complies with USP-NF 30 788, 
European and Asia Paciﬁ  c Pharmacopoeia speciﬁ  cations 
for particulate matter in injections under all clinical use 
conditions because it is tolerant to variability in pH and 
metal ion concentrations of commercial solutions used in 
the clinical setting. The variabilities of actual pH and 
metal ion concentrations in commercial IV solutions 
and diluents are unknown to the pharmacist and nurse 
end-user.
(2) The product maintains chemical and physical stability 
under the conditions encountered in the clinical ﬁ  eld of 
use where commercial diluents, such as 5% dextrose solu-
tion with potential variables of pH and leachable metal 
ions, are used for admixture preparation for parenteral 
administration. Regardless of the pH or zinc content of 
an admixture diluent or IV solution, reformulated Zosyn 
will maintain potency and lessen the level of particulates 
infused into patients.
(3) The product is compatible with calcium-containing 
Ringer’s solutions (as lactate or acetate) or Hartmann’s 
solution.
(4) The reformulated product provides the capability of 
simultaneous Y-site coadministration of amikacin (with 
0.9% NaCl or 5% dextrose) and gentamicin (with 0.9% 
NaCl), without compromising either drug’s potency, and 
provides useful options for the administration of Zosyn, 
especially for the treatment of nosocomially-acquired 
pneumonia.Therapeutics and Clinical Risk Management 2008:4(2) 314
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(5) Based on the recent stability data, the expiration dating 
of reformulated Zosyn has been extended to 36 months 
from its previously reduced dating of 24 months.
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